Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 304 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Enzalutamide August 9, 2024 Cancer and Climate Change: The Health Threats of Unnatural Disasters April 5, 2023 Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed... May 31, 2023 A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality May 11, 2026 Load more HOT NEWS PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable... Lisocabtagene Maraleucel in Relapsed or Refractory Large B-cell Lymphomas How longer waiting times are impacting teens and young adults FDA Grants Accelerated Approval to Futibatinib for Cholangiocarcinoma
